Respiratory Syncytial Virus (RSV) Market

DelveInsight’s ‘Respiratory syncytial virus (RSV) - Market Insights, Epidemiology, and Market Forecast–2032’ report delivers an in-depth understanding of Respiratory syncytial virus (RSV) historical and forecasted epidemiology as well as the Respiratory syncytial virus (RSV) market trends in the United States.

 

The Respiratory syncytial virus (RSV) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted US RSV market size. The report also covers the RSV procedure, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

• The United States

Study Period: 2019–2032

Respiratory syncytial virus (RSV) Understanding

Respiratory syncytial virus (RSV) Overview

RSV is a non-segmented virus with a negative sense single-stranded RNA genome encoding 11 proteins. Out of those, two surface transmembrane proteins, G and F, have been shown to play a key role in RSV binding and fusion, respectively. The virus is classified into two subtypes: A and B, with about 50% genetic diversity in the G gene and 10% differences in the F gene. Due to less antigenic variability of the F protein compared with the G protein, this protein is the main target of research for developing antivirals as well as anti-RSV vaccines.

 

Respiratory Syncytial Virus (RSV) is a common virus that infects children and adults; however, children younger than two years of age tend to develop more serious respiratory symptoms. Although respiratory syncytial virus (RSV) disease is self-limiting in otherwise healthy children and adults, serious lower respiratory tract infections (LRTI) such as bronchiolitis and pneumonia requiring hospitalization can occur in infants, high-risk children, adults with comorbidities, and elderly adults.

Continued in the report… 

 

Pathophysiology

RSV is the most common agent to cause lower respiratory tract infections (LRTI) among children below 5 years. Most of those acquire mild to moderate disease manifestations, and about 2–3% progress to severe illness resulting in hospitalization. Factors contributing to RSV pathogenesis and disease severity could be a viral, host, and environmental factors.

Continued in the report…

 

Diagnosis

RSV is one of the most common agents of upper and lower respiratory illnesses in infants and children worldwide. Infected individuals may present with mild, cold-like symptoms that are clinically indistinguishable from other viral respiratory infections. RSV typically occurs during the late fall, winter, and spring months and is generally self-limiting.

 

However, RSV can also manifest as severe infections, such as bronchiolitis and pneumonia, and is a significant cause of morbidity and mortality in young children, older adults, and immunocompromised patients.

 

RSV is usually diagnosed based on clinical presentation and patient history; however, the following populations warrant laboratory testing during RSV season if they present with severe respiratory illness:

• Young children (especially infants younger than 6 months)
• Adults 65 years or older
• Those with underlying heart and lung diseases (e.g., congestive heart failure, chronic obstructive pulmonary disease)

Continued in the report…

 

Treatment and Management

 

Supportive care

Supportive care is the mainstay of treatment for RSV bronchiolitis. Most infants can be managed at home, but those who are ill-appearing, dehydrated, have poor feeding, apnea, develop respiratory distress or require supplemental oxygen should be considered for hospitalization. The typical length of stay in the hospital ranges 3–7 days.

 

Supportive care includes hydration (i.e., oral or intravenous), clearing nasal obstruction with saline nose drops, nasal bulb suction or deep suctioning in the hospital, and nutrition for the patient. Oral feedings should be encouraged. Temporary feeding tubes (e.g., nasogastric) may be required in rare situations. Oxygen may be needed in those struggling to keep their oxygen saturation >90%, and it is recommended for patients whose saturations are consistently <90%. Mechanical ventilation is considered in those with respiratory failure and/or severe apnea.

Continued in the report…..

Respiratory syncytial virus (RSV) Epidemiology  

The epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of Respiratory syncytial virus (RSV) in the United States, Type-specific Incident Cases of Respiratory syncytial virus (RSV) in the United States between 2019 to 2032.

 

Key Findings

• In 2021, the total cases of Respiratory syncytial virus (RSV) in the US were 4,879,725, and these cases are anticipated to increase during the study period.
• In terms of type-specific cases of RSV, the cases of RSV-Type A are more in comparison to RSV- Type B across the US in case of children.
• In adults, RSV-Type B cases were found slightly higher than RSV-Type A cases, in the US.
• Total incident cases of RSV were found highest in below 5 years, followed by 65 years and above, and the least number of cases were found in 5 to 64 years age group.

Respiratory syncytial virus (RSV) Drug Chapters

Respiratory syncytial virus (RSV) Emerging Drugs

 

MVA-BN-RSV Vaccine: Bavarian Nordic

Bavarian Nordic is developing a vaccine candidate, MVA-BN RSV, to prevent RSV in older adults. The vaccine incorporates five distinct RSV antigens to stimulate a broad immune response against both RSV subtypes (A and B), thus mimicking the immune response observed following a natural response to an RSV infection. The vaccine candidate is based on Bavarian Nordic’s proven MVA-BN platform technology employed in several approved vaccines. Currently, the vaccine is under investigation in Phase III clinical trial, which is anticipated to be completed by 2024.

Product details in the report…

 

RSVpreF (PF-06928316): Pfizer

Pfizer’s investigational RSV vaccine candidate, RSVpreF, builds on foundational basic science discoveries, including those made at the National Institutes of Health (NIH), which detailed the crystal structure of prefusion F, a key form of the viral fusion protein (F) that RSV uses to attack human cells. The NIH research showed that antibodies specific to the prefusion form were highly effective at blocking virus infection, suggesting a prefusion F-based vaccine may confer optimal protection against RSV. After this important discovery, Pfizer tested numerous versions of the viral protein and identified those that elicited a strong antiviral immune response in preclinical evaluation.

Products detail in the report…

 

RSVPreF3 (GSK3844766A) Vaccine: GlaxoSmithKline

GSK3844766A contains a recombinant subunit pre-fusion RSV antigen combined with GSK’s proprietary AS01 adjuvant, which is also used in the company’s shingles vaccine. The antigen plus adjuvant combination may help overcome the natural age-related decline in immunity that contributes to the challenge of protecting older adults from RSV disease.

Product details in the report…

List to be continued in the report…

Respiratory syncytial virus (RSV) Market Outlook

While the understanding of RSV pathogenesis and viral biology has increased over time, prevention of the virus is still lacking, often with severe disease burdens. Treatment for RSV infection is currently limited to supportive care and prophylactic antibody use. It may include hydration, supplemental oxygen, suctioning of airways, and mechanical ventilation when needed.

 

Bronchodilators such as albuterol have long been used and studied in RSV bronchiolitis. Unfortunately, there is no clear consensus as to their effectiveness. Although extensive research has gone into studying the effect of bronchodilators in young infants and children, very limited studies or recommendations are available for adult patients with RSV infection. Because adults with RSV lower respiratory infections often have co-infections and multiple comorbidities, it is much harder to develop a guideline that applies to such a heterogeneous population.

 

Nebulized 3% saline solution has also been studied as a treatment for RSV bronchiolitis. Although there may be a role for nebulized hypertonic saline in the inpatient setting, its acute use in the ED appeared to be limited in the current studies. In the case of corticosteroids, there was no statistically significant benefit on hospital stay or clinical outcomes with the use of corticosteroids compared with placebo.

Continued in the report…..

Key Findings

• The market size of Respiratory syncytial virus (RSV) in the US was observed to be USD 1,037 million in 2021.
• In 2021, palivizumab generated a revenue of around USD 256.5 million.
• BEYFORTUS (nirsevimab) is expected to capture significant market share in the upcoming years.

 

The United States Market Outlook

This section provides the total Respiratory syncytial virus (RSV) market size and market size by therapies in the United States.

Respiratory syncytial virus (RSV) Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Respiratory syncytial virus (RSV) market or expected to get launched in the market during the study period 2019–2032. The analysis covers the Respiratory syncytial virus (RSV) market uptake by drugs; patient uptake by therapies; and sales of each drug. 

 

This helps in understanding the drugs with the most rapid uptake, and reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Respiratory syncytial virus (RSV) Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyzes key players involved in developing targeted therapeutics.

 

Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions, merger, licensing, and patent details for Respiratory syncytial virus (RSV) emerging therapies.

Reimbursement Scenario in Respiratory syncytial virus (RSV)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitive market Intelligence analysis of the Respiratory syncytial virus (RSV) market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers a descriptive overview of Respiratory syncytial virus (RSV), explaining its procedure, types, indications, and currently available therapies.
• Comprehensive insight has been provided into Respiratory syncytial virus (RSV) epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for Respiratory syncytial virus (RSV) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of the Respiratory syncytial virus (RSV) market; historical and forecasted is included in the report, covering the US drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the US Respiratory syncytial virus (RSV) market.

Report Highlights

• The robust pipeline with novel MOA and oral ROA, increasing prevalence, and effectiveness of drugs will positively drive the Respiratory syncytial virus (RSV) market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Respiratory syncytial virus (RSV) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition using Respiratory syncytial virus (RSV).
• Major players are involved in developing therapies for Respiratory syncytial virus (RSV). The launch of emerging therapies will significantly impact the Respiratory syncytial virus (RSV) market.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Respiratory syncytial virus (RSV) Report Insights

• Patient Population
• Therapeutic Approaches
• Respiratory syncytial virus (RSV) Pipeline Analysis
• Respiratory syncytial virus (RSV) Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Respiratory syncytial virus (RSV) Report Key Strengths

• 11 Years Forecast
• The US Coverage
• Respiratory syncytial virus (RSV) Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Respiratory syncytial virus (RSV) Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• SWOT analysis

Key Questions

Market Insights:

• What was the Respiratory syncytial virus (RSV) market share (%) distribution in 2019 and how it would look like in 2032?
• What would be the Respiratory syncytial virus (RSV) total market size as well as market size by therapies across the US during the forecast period (2022–2032)?
• What are the key findings pertaining to the market across the US and which country will have the largest Respiratory syncytial virus (RSV) market size during the forecast period (2022–2032)?
• At what CAGR, the Respiratory syncytial virus (RSV) market is expected to grow at the US level during the forecast period (2022–2032)?
• What would be the Respiratory syncytial virus (RSV) market outlook across the US during the forecast period (2022–2032)?
• What would be the Respiratory syncytial virus (RSV) market growth till 2032 and what will be the resultant market size in the year 2032?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

• What are the risk, burdens, and unmet needs of Respiratory syncytial virus (RSV)?
• What is the historical Respiratory syncytial virus (RSV) patient pool in the United States?
• What would be the forecasted patient pool of Respiratory syncytial virus (RSV) at the US level?
• What will be the growth opportunities across the US with respect to the patient population pertaining to Respiratory syncytial virus (RSV)?
• At what CAGR are these cases expected to grow across the US during the forecast period (2022–2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current treatment practices in Respiratory syncytial virus (RSV) along with the approved therapy?
• What are the current treatment guidelines for Respiratory syncytial virus (RSV)?
• What are the Respiratory syncytial virus (RSV) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
• How many companies are developing therapies for Respiratory syncytial virus (RSV)?
• How many emerging therapies are in the mid-stage and late stages of development for Respiratory syncytial virus (RSV)?
• What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Respiratory syncytial virus (RSV) therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Respiratory syncytial virus (RSV) and their status?
• What are the key designations that have been granted for the emerging therapies for Respiratory syncytial virus (RSV)?
• What is the US historical and forecasted market of Respiratory syncytial virus (RSV)?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving Respiratory syncytial virus (RSV).
• To understand the future market competition in the Respiratory syncytial virus (RSV) market and an insightful review of the market.
• Organize sales and marketing efforts by identifying the best opportunities for Respiratory syncytial virus (RSV) in the US.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the Respiratory syncytial virus (RSV) market.
• To understand the future market competition in the Respiratory syncytial virus (RSV) market.